Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Abstract: A display panel includes a display region and a photoelectric sensing region which includes a light transmitting region and a frame region surrounding the light transmitting region; the frame region includes a first region surrounding the light transmitting region, a second region on a side of the first region away from the light transmitting region and surrounding the first region, and a third region between the second region and the display region. The spacers are in an array and in the display region but not in the light transmitting region. A plurality of first support pillars are in the first region, arranged around the light transmitting region, and spaced from each other. A plurality of second support pillars are in the second region, around the second region, and spaced from each other. A plurality of third support pillars are in the third region in an array.

Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV or HMPV infection. The invention also relates to methods of treating an RSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: A fly ash recycling gasification furnace includes a fly ash burner, an ash remover, a fly ash storage tank, a variable pressure lock hopper, a fly ash blending system, an exhaust filter, and a backflushing nitrogen buffer tank. The fly ash burner is located on an inner wall of a hearth of the gasification furnace. The ash remover has an inlet connected to an outlet of a waste boiler of the gasification furnace. The fly ash storage tank is connected to a pressurized nitrogen inlet pipe, and a bottom outlet of the ash remover. The variable pressure lock hopper is connected to the fly ash storage tank. The fly ash blending system is connected to the variable pressure lock hopper and the fly ash burner. The exhaust filter is connected to the storage tank, the lock hopper and the blending system. The buffer tank is connected to the exhaust filter.

Abstract: A fly ash recycling gasification furnace includes a fly ash burner, an ash remover, a fly ash storage tank, a variable pressure lock hopper, a fly ash blending system, an exhaust filter, and a backflushing nitrogen buffer tank. The fly ash burner is located on an inner wall of a hearth of the gasification furnace. The ash remover has an inlet connected to an outlet of a waste boiler of the gasification furnace. The fly ash storage tank is connected to a pressurized nitrogen inlet pipe, and a bottom outlet of the ash remover. The variable pressure lock hopper is connected to the fly ash storage tank. The fly ash blending system is connected to the variable pressure lock hopper and the fly ash burner. The exhaust filter is connected to the storage tank, the lock hopper and the blending system. The buffer tank is connected to the exhaust filter.